Renee A. Nolan is partner at Lowey Dannenberg. She is a member of the Healthcare and Antitrust practice group, focusing on recovery litigation for pharmaceutical overcharge and fraud on behalf of large healthcare clients.

Notable cases:

Ms. Nolan has recovered $145 million for classes of health plans and insurers as co-lead counsel in In re Ranbaxy Generic Drug Antitrust Litigation before Judge Nathaniel Gorton in the District of Massachusetts.  The End-Payor Plaintiffs alleged that generic drug maker Ranbaxy violated antitrust and consumer protection laws when it engaged in a decade-long scheme obtaining lucrative first-to-file Abbreviated New Drug Applications for several generic drugs. This would have given Ranbaxy 180 days of market exclusivity upon generic entry, but rampant GMP violations at their manufacturing facilities left them without the ability to manufacture the drugs when they received approval from the FDA. These manufacturing problems created a bottleneck in the generic market that prevented the plaintiffs from obtaining cheaper generic drugs resulting in overcharges to the End-Payor Plaintiffs. Ms. Nolan was responsible for managing a team of lawyers for the End-Payor Plaintiffs and involved in nearly every aspect of the case, from drafting the complaint through class certification and up to the eve of trial. Through her efforts the classes were able to achieve one of the largest end-payor pharmaceutical antitrust settlements in recent history.

Ms. Nolan represents a group of six large insurers in Roanoke County Circuit Court alleging RICO and antitrust violations against pharmaceutical company Indivior for its multi-faceted scheme to raise prices of the drug Suboxone, a drug used by vulnerable, opioid-addicted patients. The suit alleges Indivior utilized a product hop scheme, kickbacks to physicians, off label promotion, and abuse of several FDA processes to keep the price of Suboxone at supracompetitive levels at the expense of payors.

Ms. Nolan was also part of a team that recovered overcharges for a large group of insurers alleging they were induced to pay billions of dollars for adulterated and falsely marketed drugs that came from a GlaxoSmithKline factory with long-term good manufacturing practice problems that the pharmaceutical company hid from the FDA and payors.

Achievements and Professional Activities:

In 2022, Ms. Nolan received the American Antirust Institute’s Award for Outstanding Antitrust Litigation Achievement by a Young Lawyer for her work in the Ranbaxy Generic Antitrust Litigation.

In 2020, Ms. Nolan was appointed to a three-year term as a member of the Hearing Committee serving the Disciplinary Board of the Supreme Court of Pennsylvania.

Ms. Nolan is an active member of the Pennsylvania and Montgomery Bar Associations. Additionally, she regularly serves as an arbitrator on arbitration panels in the Montgomery County Court of Common Pleas.

Background:

Prior to joining Lowey, Ms. Nolan was an associate at a prominent insurance defense firm in suburban Philadelphia, where she was responsible for all aspects of a large caseload of general liability matters from inception through arbitration or settlement. Her practice included medical malpractice litigation representing doctors, medical professionals, and healthcare institutions. In addition, she was responsible for consulting with experts to perform pre-suit analysis of potential medical malpractice claims for a large hospital chain.

Ms. Nolan graduated from Villanova School of Law in 2013, where she researched legal ethics and healthcare issues as a research assistant for a law clinic professor. During law school, Ms. Nolan was a judicial extern for the Honorable Susan Peikes Gantman of the Superior Court of Pennsylvania and a summer intern for the Honorable Thomas P. Rogers of the Court of Common Pleas.

Ms. Nolan received her undergraduate degree from the Honors Program of Villanova University in 2008 with a degree in Classical Studies.